The nation of Zimbabwe has rejected a substantial American health deal worth 367 million US dollars (£272m) over five years over Washington's insistence on confidential information.
This move came to light after a official document from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "skewed".
An official representative later explained that the United States was requesting biological samples for research and commercial gain but refused to share the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for continued talks to find a deal acceptable to both sides so the country's vital HIV treatment initiative can be sustained.
Wider Context
This rejection comes after a comparable situation in Kenya, where a high court halted a similar health funding agreement after legal challenges were raised about the safety of citizens' health data.
Since resuming office last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had managed aid for the American government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to enhance transparency and responsibility.
As per statements, Sixteen African countries have so far signed these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered extraordinary benefits for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to provide its biological resources and data for a long time, with no equivalent assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"Put simply, our country would provide the basic resources for medical research with no certainty that the final treatments would be available to our people if a new health crisis emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining frameworks previously set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with potential pandemics.
"This system is designed to ensure that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," he added.
"We are open to ongoing dialogue with our American counterparts on how future collaboration could be structured in a way that respects the sovereignty and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but recommended that talks should continue considering a large portion of the country's Aids initiatives were funded by external financing.
"In cases where specific concerns exist, including those relating to data governance or agreement terms, these can frequently be resolved through technical clarification and mutually agreed protections," it said.
The situation underscores the ongoing tensions between receiving crucial international aid and protecting a country's data in an ever more data-driven world.